Decoy oligodeoxynucleotide targeting activator protein-1 (AP-1) attenuates intestinal inflammation in murine experimental colitis

Laboratory Investigation

Volumn 88, Issue 6, 2008, Pages 652-663

  Moriyama, Ichiro ^a   Ishihara, Shunji ^a,d   Rumi, M Azharul Karim ^b   Aziz, M D Monowar ^a   Mishima, Yoshiyuki ^a   Oshima, Naoki ^a   Kadota, Chikara ^a   Kadowaki, Yasunori ^a   Amano, Yuji ^c   Kinoshita, Yoshikazu ^a  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^c SHIMANE UNIVERSITY HOSPITAL   (Japan)

^d SHIMANE UNIVERSITY   (Japan)

Author keywords

AP 1; Decoy oligodeoxynucleotide; Experimental colitis; Inflammatory bowel disease; NF B

Indexed keywords

DECOY OLIGODEOXYNUCLEOTIDE; DEXTRAN SULFATE; FLAGELLIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 8; LUCIFERASE; MYELOPEROXIDASE; OLIGODEOXYNUCLEOTIDE; SCRAMBLED OLIGODEOXYNUCLEOTIDE; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CANCER CELL CULTURE; COLITIS; COLON ADENOCARCINOMA; CONTROLLED STUDY; DRUG TARGETING; GENETIC TRANSFECTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPORTER GENE; WEIGHT REDUCTION;

ANIMALS; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; COLITIS, ULCERATIVE; COLONIC NEOPLASMS; DEXTRAN SULFATE; FLOW CYTOMETRY; FLUORESCEIN-5-ISOTHIOCYANATE; FLUORESCENT DYES; GENES, REPORTER; HUMANS; INFLAMMATION; INTERLEUKIN-8; LUCIFERASES; MICE; MICE, INBRED BALB C; OLIGONUCLEOTIDES; RNA, MESSENGER; SPECIFIC PATHOGEN-FREE ORGANISMS; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 44349111668     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2008.38     Document Type: Article

References (64)

1. Hibi T, Ogata H. Novel pathophysiological concepts of inflammatory bowel disease. J Gastroenterol 2006;41:10-16.
2. Sands BE. Inflammatory bowel disease: past, present, and future. J Gastroenterol 2007;42:16-25.
3. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003;3:521-533.
4. Macdonald TT, Monteleone G. Immunity, inflammation, and allergy in the gut. Science 2005;307:1920-1925.
5. Rogler G. Update in inflammatory bowel disease pathogenesis. Curr Opin Gastroenterol 2004;20:311-317.
6. Mudter J, Neurath MF. IL-6 signaling in inflammatory bowel disease: pathophysiological role and clinical relevance. Inflamm Bowel Dis 2007;13:1016-1023.
7. Ishihara S, Rumi MA, Ortega-Cava CF, et al. Therapeutic targeting of toll-like receptors in gastrointestinal inflammation. Curr Pharm Des 2006;12:4215-4228.
8. Abreu MT, Fukata M, Arditi M. TLR signaling in the gut in health and disease. J Immunol 2005;174:4453-4460.
9. Ortega-Cava CF, Ishihara S, Rumi MA, et al. Strategic compartmentalization of toll-like receptor 4 in the mouse gut. J Immunol 2005;170:3977-3985.
10. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007;369:1641-1657.
11. Buning C, Lochs H. Conventional therapy for Crohn's disease. World J Gastroenterol 2006;12:4794-4806.
12. Dubinsky MC. Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. Clin Gastroenterol Hepatol 2004;2:731-743.
13. Domenech E. Inflammatory bowel disease: current therapeutic options. Digestion 2006;73(Suppl 1):S67-S76.
14. Kusugami K, Ina K, Ando T, et al. Immunomodulatory therapy for inflammatory bowel disease. J Gastroenterol 2004;39:1129-1137.
15. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-1549.
16. Sands BE, Blank MA, Patel K, et al. Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol 2004;2:912-920.
17. Nakamura K, Honda K, Mizutani T, et al. Novel strategies for the treatment of inflammatory bowel disease: selective inhibition of cytokines and adhesion molecules. World J Gastroenterol 2006;12:4628-4635.
18. Ito H, Takazoe M, Fukuda Y, et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 2004;126:989-996.
19. Viola JP, Rao A. Molecular regulation of cytokine gene expression during the immune response. J Clin Immunol 1999;19:98-108.
20. Holloway AF, Rao S, Shannon MF. Regulation of cytokine gene transcription in the immune system. Mol Immunol 2002;38:567-580.
21. Wagner EF, Eferl R. Fos/AP-1 proteins in bone and the immune system. Immunol Rev 2005;208:126-140.
22. Eferl R, Wagner EF. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 2003;3:859-868.
23. Chinenov Y, Kerppola TK. Close encounters of many kinds: Fos-Jun interactions that mediate transcription regulatory specificity. Oncogene 2001;20:2438-2452.
24. Stepniak E, Ricci R, Eferl R, et al. c-Jun/AP-1 controls liver regeneration by repressing p53/p21 and p38 MAPK activity. Genes Dev 2006;20:2306-2314.
25. Karin M. The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem 1995;270:16483-16486.
26. Whitmarsh AJ, Davis RJ. Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J Mol Med 1996;74:589-607.
27. Aud D, Peng SL. Mechanisms of disease: transcription factors in inflammatory arthritis. Nat Clin Pract Rheumatol 2006;2:434-442.
28. Pastore S, Mascia F, Mariotti F, et al. ERK1/2 regulates epidermal chemokine expression and skin inflammation. J Immunol 2005;174:5047-5056.
29. Bozinovski S, Jones JE, Vlahos R, et al. Granulocyte/macrophage- colony-stimulating factor (GM-CSF) regulates lung innate immunity to lipopolysaccharide through Akt/Erk activation of NFkappa B and AP-1 in vivo. J Biol Chem 2002;277:42808-42814.
30. Ohkubo Y, Arima M, Arguni E, et al. A role for c-fos/activator protein 1 in B lymphocyte terminal differentiation. J Immunol 2005;174:7703-7710.
31. Ishiguro Y, Yamagata K, Sakuraba H, et al. Macrophage migration inhibitory factor and activator protein-1 in ulcerative colitis. Ann N Y Acad Sci 2006;1029:348-349.
32. Andoh A, Zhang Z, Inatomi O, et al. Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. Gastroenterology 2005;129:969-984.
33. Isomura I, Morita A. Regulation of NF-kappaB signaling by decoy oligodeoxynucleotides. Microbiol Immunol 2006;50:559-563.
34. Mann MJ, Dzau VJ. Therapeutic applications of transcription factor decoy oligonucleotides. J Clin Invest 2000;106:1071-1075.
35. Matsuda N, Hattori Y, Takahashi Y, et al. Therapeutic effect of in vivo transfection of transcription factor decoy to NF-kappaB on septic lung in mice. Am J Physiol Lung Cell Mol Physiol 2004;287:L1248-L1255.
36. Tomita T, Takano H, Tomita N, et al. Transcription factor decoy for NF-kappa B inhibits cytokine and adhesion molecule expressions in synovial cells derived from rheumatoid arthritis. Rheumatology (Oxford) 2000;39:749-757.
37. Morishita R, Tomita N, Kaneda Y, et al. Molecular therapy to inhibit NF-kappa B activation by transcription factor decoy oligonucleotides. Curr Opin Pharmacol 2004;4:139-146.
38. Ahn JD, Morishita R, Kaneda Y, et al. Inhibitory effects of novel AP-1 decoy oligodeoxynucleotides on vascular smooth muscle cell proliferation in vitro and neointimal formation in vivo. Circ Res 2002;90:1325-1332.
39. Holschermann H, Stadlbauer TH, Wagner AH, et al. STAT-1 and AP-1 decoy oligonucleotide therapy delays acute rejection and prolongs cardiac allograft survival. Cardiovasc Res 2006;71:527-536.
40. Desmet C, Gosset P, Henry E, et al. Treatment of experimental asthma by decoy-mediated local inhibition of activator protein-1. Am J Respir Crit Care Med 2005;172:671-678.
41. Henriquet C, Gougat C, Combes A, et al. Differential regulation of RANTES and IL-8 expression in lung adenocarcinoma cells. Lung Cancer 2007;56:167-174.
42. Vowinkel T, Kalogeris TJ, Mori M, et al. Impact of dextran sulfate sodium load on the severity of inflammation in experimental colitis. Dig Dis Sci 2004;49:556-564.
43. Hurme M, Matikainen S. Okadaic acid, a phosphatase inhibitor, enhances the phorbol ester-induced interleukin-1 beta expression via an AP-1-mediated mechanism. Scand J Immunol 1993;38:570-574.
44. Newell CL, Deisseroth AB, Lopez-Berestein G. Interaction of nuclear proteins with an AP-1/CRE-like promoter sequence in the human TNF-alpha gene. J Leukoc Biol 1994;56:27-35.
45. Shen G, Jeong WS, Hu R, et al. Regulation of Nrf2, NF-kappaB, and AP-1 signaling pathways by chemopreventive agents. Antioxid Redox Signal 2005;7:1648-1663.
46. Caramori G, Adcock I. Anti-inflammatory mechanisms of glucocorticoids targeting granulocytes. Curr Drug Targets Inflamm Allergy 2005;4:455-463.
47. Milde-Langosch K. The Fos family of transcription factors and their role in tumourigenesis. Eur J Cancer 2005;41:2449-2461.
48. Lichtenstein GR, Yan S, Bala M, et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005;128:862-869.
49. Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2006;132:863-873.
50. Hommes DW, Mikhajlova TL, Stoinov S, et al. Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Gut 2006;55:1131-1137.
51. Reinisch W, Hommes DW, Van Assche G, et al. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease. Gut 2006;55:1138-1144.
52. Mannon PJ, Fuss IJ, Mayer L, et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 2004;351:2069-2079.
53. Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 2007;132:1672-1683.
54. Park KK, Deok Ahn J, Lee IK, et al. Inhibitory effects of novel E2F decoy oligodeoxynucleotides on mesangial cell proliferation by coexpression of E2F/DP. Biochem Biophys Res Commun 2003;308:689-697.
55. Chae YM, Park KK, Magae J, et al. Sp1-decoy oligodeoxynucleotide inhibits high glucose-induced mesangial cell proliferation. Biochem Biophys Res Commun 2004;319:550-555.
56. Chan KS, Sano S, Kiguchi K, et al. Disruption of Stat3 reveals a critical role in both the init and the promotion stages of epithelial carcinogenesis. J Clin Invest 2004;114:720-728.
57. Sumi K, Yokozeki H, Wu MH, et al. In vivo transfection of a cis element 'decoy' against signal transducers and activators of the transcription 6 (STAT6) binding site ameliorates the response of contact hypersensitivity. Gene Therapy 2004;11:1763-1771.
58. Leong PL, Andrews GA, Johnson DE, et al. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci USA 2003;100:4138-4143.
59. Fichtner-Feigl S, Fuss IJ, Preiss JC, et al. Treatment of murine Th1- and Th2-mediated inflammatory bowel disease with NF-kappa B decoy oligonucleotides. J Clin Invest 2005;115:3057-3071.
60. Suzuki J, Ito H, Gotoh R, et al. Initial clinical cases of the use of a NF-kB decoy at the site of coronary stenting the prevention of restenosis. Circ J 2004;68:270-271.
61. De Rosa G, Maiuri MC, Ungaro F, et al. Enhanced intracellular uptake and inhibition of NF-kappaB activation by decoy oligonucleotide released from PLGA microspheres. J Gene Med 2005;7:771-781.
62. Inagaki H, Suzuki J, Ogawa M, et al. Ultrasound-microbubble- mediated NF-kappa B decoy transfection attenuates neointimal formation after arterial injury in mice. J Vasc Res 2006;43:12-18.
63. Tomita T, Takeuchi E, Tomita N, et al. Suppressed severity of collagen-induced arthritis by in vivo transfection of nuclear factor kappaB decoy oligodeoxynucleotides as a gene therapy. Arthritis Rheum 1999;42:2532-2542.
64. Yoshimura S, Morishita R, Hayashi K, et al. Inhibition of intimal hyperplasia after balloon injury in rat carotid artery model using cis-element 'decoy' of nuclear factor-kappa B-binding site as a novel molecular strategy. Gene Therapy 2001;8:1635-1642.